Baili Tianheng's Cancer Drug Combo Earns Breakthrough Designation in China

Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (SSE: 688506) announced its novel antibody-drug conjugate has received a key regulatory nod in China. The combination therapy involving its drug Yizekang® was granted Breakthrough Therapy Designation for the first-line treatment of an aggressive form of breast cancer.

Regulatory Milestone

According to a company announcement, the Center for Drug Evaluation (CDE) of China's National Medical Products Administration has included the new treatment regimen in its Breakthrough Therapy Program. The public comment period for the designation has recently concluded.

The designation applies to Yizekang® (iza-bren, BL-B01D1) used in combination with a PD-1 monoclonal antibody. The specific indication is for the first-line treatment of PD-L1 positive, locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC).

This marks the first time a Yizekang®-based treatment has received Breakthrough Therapy Designation for a first-line indication, signaling a significant step in expanding the drug's potential use.

About the Drug

Ad

Baili Tianheng describes Yizekang® as a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC). The company states it is the first and only approved therapy of its kind globally.

ADCs are a class of targeted cancer drugs designed to deliver chemotherapy directly to cancer cells, potentially minimizing damage to healthy cells. Yizekang®'s bispecific nature allows it to target two distinct proteins, EGFR and HER3, which are often involved in tumor growth.

Context and Implications

Breakthrough Therapy Designation is intended to expedite the development and review of drugs that treat serious conditions and have shown preliminary clinical evidence of substantial improvement over available therapies. This designation can potentially shorten the timeline to full regulatory approval for this new indication.

Triple-negative breast cancer is a particularly aggressive subtype with limited treatment options. Gaining a foothold as a first-line therapy in the PD-L1 positive patient population could represent a significant commercial opportunity for Baili Tianheng and offer a new option for patients, pending final trial results and market approval.